{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:20:15Z","timestamp":1780482015033,"version":"3.54.1"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00CA237744"],"award-info":[{"award-number":["R00CA237744"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FU 356\/12-1"],"award-info":[{"award-number":["FU 356\/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jgo.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:23:33Z","timestamp":1669278213000},"page":"101406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hypomethylating agent-based therapies in older adults with acute myeloid leukemia \u2013 A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee"],"prefix":"10.1016","volume":"14","author":[{"given":"Nina Rosa","family":"Neuendorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Meckstroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Thibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabiel","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Yu","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.C.","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Klingen","family":"Gj\u00e6rde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0005","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3324\/haematol.2008.000497","article-title":"Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives","volume":"93","author":"Mikkael","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0010","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jgo.2022.11.005_bb0015","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","article-title":"Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries","volume":"36","author":"R\u00e9cher","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgo.2020.11.001","article-title":"Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades","volume":"12","author":"Ihlow","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2022.11.005_bb0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11899-019-00552-6","article-title":"Health-related quality of life and treatment of older adults with acute myeloid leukemia: a young international society of geriatric oncology review paper","volume":"14","author":"Loh","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"10.1016\/j.jgo.2022.11.005_bb0035","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1634\/theoncologist.2018-0890","article-title":"Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists","volume":"24","author":"Loh","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/phar.1316","article-title":"Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed\/refractory adult patients with acute myeloid leukemia","volume":"33","author":"Williams","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"20","key":"10.1016\/j.jgo.2022.11.005_bb0050","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","article-title":"Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines","volume":"69","author":"Schaefer","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12964-017-0168-z","article-title":"The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation","volume":"15","author":"Wolff","year":"2017","journal-title":"Cell Commun Signal"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.jgo.2022.11.005_bb0070","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa2119771","article-title":"Demethylation and up-regulation of an oncogene after hypomethylating therapy","volume":"386","author":"Liu","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clml.2021.09.021","article-title":"Oral azacitidine (CC-486) for the treatment of myeloid malignancies","volume":"22","author":"Garcia-Manero","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"10.1016\/j.jgo.2022.11.005_bb0080","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","article-title":"Clinical update on hypomethylating agents","volume":"110","author":"Duchmann","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jgo.2022.11.005_bb0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.HS9.0000561796.30124.a4","article-title":"Results of astral-1 study, a phase 3 randomized trial of guadecitabine (G) vs treatment choice (TC) in treatment na\u00efve acute myeloid leukemia (TN-AML) not eligible for intensive chemotherapy (IC): S879","volume":"3","author":"Fenaux","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.jgo.2022.11.005_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-020-00160-8","article-title":"Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis","volume":"9","author":"Wen","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"22","key":"10.1016\/j.jgo.2022.11.005_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225677","article-title":"Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: a systematic review and meta-analysis","volume":"13","author":"Saiz-Rodr\u00edguez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ki.2015.230","article-title":"A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010","volume":"88","author":"Mills","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/phar.1371","article-title":"A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous azacitidine and its pharmacokinetics in patients with severe renal impairment","volume":"34","author":"Laille","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.leukres.2013.05.005","article-title":"Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment","volume":"37","author":"Douvali","year":"2013","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLML.2010.n.032","article-title":"Feasibility of therapy with hypomethylating agents in patients with renal insufficiency","volume":"10","author":"Batty","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1078155217702213","article-title":"A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine","volume":"24","author":"Levine","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0140","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.3109\/10428194.2012.688201","article-title":"A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine","volume":"53","author":"Ham","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/10428194.2020.1838505","article-title":"Azacitidine is removed effectively by hemodialysis","volume":"62","author":"Beer","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jgo.2022.11.005_bb0155","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0160","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/cncr.33403","article-title":"A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia","volume":"127","author":"Vives","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020415","article-title":"Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian azacitidine registry of the AGMT study group","volume":"18","author":"Pleyer","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jgo.2022.11.005_bb0170","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.7150\/jca.18686","article-title":"Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials","volume":"8","author":"Agarwal","year":"2017","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0175","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/10428194.2014.951845","article-title":"Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study","volume":"56","author":"He","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.jgo.2022.11.005_bb0180","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood.V128.22.2799.2799","article-title":"Deficiency of current acute myeloid leukemia (AML) response criteria to predict response to hypomethylating agent therapy: the value of long-lasting stable disease","volume":"128","author":"Williams","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2022.11.005_bb0185","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-014-2126-9","article-title":"Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian azacitidine registry of the AGMT-study group","volume":"93","author":"Pleyer","year":"2014","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0190","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jgo.2022.11.005_bb0195","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.jgo.2022.11.005_bb0200","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jgo.2022.11.005_bb0210","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jgo.2022.11.005_bb0215","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jgo.2022.11.005_bb0220","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.jgo.2022.11.005_bb0235","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2022.11.005_bb0240","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jgo.2022.11.005_bb0245","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0250","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1002\/ajh.26057","article-title":"Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia","volume":"96","author":"Arslan","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jgo.2022.11.005_bb0255","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jgo.2022.11.005_bb0260","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jgo.2022.11.005_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061359","article-title":"2-Hydroxyglutarate in acute myeloid leukemia: a journey from pathogenesis to therapies","volume":"10","author":"Raimondi","year":"2022","journal-title":"Biomedicines"},{"issue":"16","key":"10.1016\/j.jgo.2022.11.005_bb0270","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0275","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/bloodadvances.2021006872","article-title":"Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101","volume":"6","author":"Ritchie","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jgo.2022.11.005_bb0280","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood.2021015200","article-title":"Toward consensus on geriatric assessment in AML","volume":"139","author":"Klepin","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jgo.2022.11.005_bb0285","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1200\/JCO.2022.40.16_suppl.6586","article-title":"Time at home among older adults with acute myeloid leukemia based on treatment intensity: a SEER-medicare analysis","volume":"40","author":"Richardson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2022.11.005_bb0290","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2021-144818","article-title":"Time spent at home among older adults with AML treated with hypomethylating agents and venetoclax","volume":"138","author":"Jensen","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jgo.2022.11.005_bb0295","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0300","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/leu.2015.346","article-title":"The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3\/ITD acute myeloid leukemia cells","volume":"30","author":"Chang","year":"2016","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.jgo.2022.11.005_bb0305","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0315","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2020.263392","article-title":"A phase I\/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"106","author":"Swaminathan","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0320","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clml.2019.10.018","article-title":"A phase II study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia","volume":"20","author":"Tomlinson","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jgo.2022.11.005_bb0330","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2022.11.005_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142249","article-title":"Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Abaza","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0345","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1002\/ajh.24980","article-title":"Intergroup LEAP trial (S1612): a randomized phase 2\/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia","volume":"93","author":"Walter","year":"2018","journal-title":"Am J Hematol"},{"issue":"Supplement_1","key":"10.1016\/j.jgo.2022.11.005_bb0350","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2019-124320","volume":"134","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2022.11.005_bb0355","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jgo.2022.11.005_bb0360","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","article-title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","volume":"132","author":"Feng","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2022.11.005_bb0365","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2020.38.15_suppl.7507","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results","volume":"38","author":"Sallman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2022.11.005_bb0370","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(21)01694-3","article-title":"AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results","volume":"21","author":"Sallman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0375","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.17823","article-title":"Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy","volume":"196","author":"Loke","year":"2022","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.jgo.2022.11.005_bb0380","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1158\/1078-0432.CCR-17-1423","article-title":"Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature","volume":"23","author":"Craddock","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0385","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10428194.2019.1665664","article-title":"Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study","volume":"61","author":"Bhatnagar","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.jgo.2022.11.005_bb0390","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2018-03-841171","article-title":"A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML","volume":"132","author":"Fathi","year":"2018","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jgo.2022.11.005_bb0395","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jgo.2022.11.005_bb0400","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0405","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clml.2018.02.017","article-title":"A phase I\/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia","volume":"18","author":"Medeiros","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.jgo.2022.11.005_bb0410","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jgo.2022.11.005_bb0415","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jgo.2022.11.005_bb0420","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0425","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3324\/haematol.2021.279174","article-title":"Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial","volume":"106","author":"Roboz","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-021-01142-x","article-title":"Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial","volume":"14","author":"Ravandi","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2022.11.005_bb0435","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.jgo.2022.11.005_bb0440","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2019-129876","article-title":"Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study","volume":"134","author":"Foran","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jgo.2022.11.005_bb0445","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jgo.2022.11.005_bb0450","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0455","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajh.26496","article-title":"Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia","volume":"97","author":"Senapati","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jgo.2022.11.005_bb0460","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0465","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbmt.2018.03.025","article-title":"Allogeneic hematopoietic stem cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: findings from an international retrospective study","volume":"24","author":"Stahl","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jgo.2022.11.005_bb0470","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-020-04333-7","article-title":"Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed\/refractory acute myeloid leukemia patients","volume":"100","author":"Zappasodi","year":"2020","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jgo.2022.11.005_bb0475","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"Supplement_1","key":"10.1016\/j.jgo.2022.11.005_bb0480","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood-2019-127251","article-title":"Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies","volume":"134","author":"Pratz","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jgo.2022.11.005_bb0485","first-page":"e71","article-title":"Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia","volume":"196","author":"Salhotra","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0490","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","article-title":"Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia","volume":"26","author":"Sandhu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0495","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0500","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2022.11.005_bb0505","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1182\/blood-2021-154392","article-title":"Outcomes are similar following allogeneic hematopoietic stem cell transplant for newly diagnosed patients who received venetoclax + azacitidine versus intensive chemotherapy","volume":"138","author":"Winters","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2022.11.005_bb0510","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-143002","article-title":"Hypomethylating agents in combination with venetoclax as a bridge to allogeneic transplant in acute myeloid leukemia","volume":"136","author":"Kennedy","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0515","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/cncr.11184","article-title":"Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias","volume":"97","author":"de Lima","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2022.11.005_bb0520","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bbmt.2016.02.003","article-title":"Addition of 10-day decitabine to fludarabine\/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses","volume":"22","author":"Cruijsen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jgo.2022.11.005_bb0525","article-title":"A retrospective observation of treatment outcomes using decitabine-combined standard conditioning regimens before transplantation in patients with relapsed or refractory acute myeloid leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0530","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MOH.0000000000000700","article-title":"Azacitidine maintenance in AML post induction and posttransplant","volume":"29","author":"Bewersdorf","year":"2022","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.09.005","article-title":"Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"36","key":"10.1016\/j.jgo.2022.11.005_bb0540","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2022.11.005_bb0545","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jgo.2022.11.005_bb0550","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0555","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2022.11.005_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.812207","article-title":"Treatment of AML relapse after Allo-HCT","volume":"11","author":"Webster","year":"2021","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2022.11.005_bb0565","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1080\/10428194.2020.1808213","article-title":"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy","volume":"61","author":"Othman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0570","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","article-title":"Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study","volume":"98","author":"Ram","year":"2019","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.jgo.2022.11.005_bb0575","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/0006-2952(73)90137-8","article-title":"Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase","volume":"22","author":"Chabner","year":"1973","journal-title":"Biochem Pharmacol"},{"issue":"20","key":"10.1016\/j.jgo.2022.11.005_bb0580","first-page":"4531","article-title":"Methylation of the 5\u2019 CpG island of the p16\/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing","volume":"55","author":"Gonzalez-Zulueta","year":"1995","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jgo.2022.11.005_bb0585","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0590","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jgo.2022.11.005_bb0595","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/10428194.2017.1365854","article-title":"Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC\/LRF score: results from the expanded international E-ALMA series (E-ALMA+)","volume":"59","author":"Falantes","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0600","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.16680","article-title":"Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients","volume":"190","author":"Peterlin","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030826","article-title":"Long-term follow-up of elderly patients with acute myeloid leukemia treated with decitabine: a real-world study of the apulian hematological network","volume":"14","author":"Dargenio","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0610","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.2018.208637","article-title":"Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia","volume":"105","author":"Chetasi","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jgo.2022.11.005_bb0615","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jgo.2022.11.005_bb0620","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jgo.2022.11.005_bb0625","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jgo.2022.11.005_bb0630","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.jgo.2022.11.005_bb0635","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.jgo.2022.11.005_bb0640","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jgo.2022.11.005_bb0645","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.31138","article-title":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia","volume":"124","author":"Roboz","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0650","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","article-title":"A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure","volume":"104","author":"S\u00e9bert","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080972","article-title":"Hypomethylating agents (HMAs) as salvage therapy in relapsed or refractory AML: an Italian multicentric retrospective study","volume":"9","author":"Lessi","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0660","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jgo.2022.11.005_bb0665","first-page":"1","article-title":"Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia","author":"Graveno","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2022.11.005_bb0670","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.2147\/CMAR.S316561","article-title":"Efficacy of venetoclax combined with decitabine-based treatment for heavily pre-treated relapsed or refractory AML patients in a real-world setting","volume":"13","author":"Tong","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.1016\/j.jgo.2022.11.005_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081684","article-title":"Venetoclax-based regimens for relapsed\/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience","volume":"10","author":"Piccini","year":"2021","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.jgo.2022.11.005_bb0680","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.33814","article-title":"Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score-matched analysis","volume":"127","author":"Maiti","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jgo.2022.11.005_bb0685","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.jgo.2022.11.005_bb0690","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of F LT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jgo.2022.11.005_bb0695","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1080\/10428194.2021.1973675","article-title":"Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine","volume":"62","author":"Venugopal","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"10.1016\/j.jgo.2022.11.005_bb0700","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406822005288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406822005288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:57:37Z","timestamp":1761818257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406822005288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1879406822005288"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2022.11.005","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypomethylating agent-based therapies in older adults with acute myeloid leukemia \u2013 A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101406"}}